Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: IPSEN PHARMA S.A.S
Man Max 99 years
IPSEN PHARMA S.A.S
Update Il y a 4 ans
Study to evaluate the efficay, safety and local tolerability of triptorelin pamoate (11,25mg) injected sub cuteanously in patients with (locally advanced or metastatic) prostate cancer
To confirm the efficacy of triptorelin pamoate (11.25 mg)prolonged release (PR) formulation by inducing castration (defined as serum testosterone level of <50 ng/dL or <1.735 nmol/L) at Day 29 and mai...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
IPSEN PHARMA S.A.S
Update Il y a 4 ans
An international multi-center, open-label study to evaluate safety, tolerability, biodistribution (distribution in the body), dosimetry (to calculate the radiation exposure of patients) and preliminary efficacy of 177Lu-OPS201 for the therapy of somatostatin receptor-positive neuroendocrine tumors (NETs). Eine internationale multizentrische, offene Studie zur Bewertung der Sicherheit, Verträglichkeit, Biodistribution (Verteilung im Körper), Dosimetrie (zur Berechnung der Strahlenbelastung der Patienten) und der vorläufigen Wirksamkeit von 177Lu-OPS201 für die Therapie Somatostatin-Rezeptor-positiver neuroendokriner Tumore (NETs)
To assess the safety and tolerability of peptide receptor radionuclide therapy (PRRT) with 177Lu-OPS201 administered in three cycles in patients with somatostatin receptor positive NETs (including pha...
Country
None
organs
None
Specialty
None
unknown
More information